Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Faris Alnezary"'
Autor:
Joanna E. Harnett, Shane P. Desselle, Marcília Baticy Fernandes, Dongning Yao, Darko Modun, Souheil Hallit, Mariam Dabbous, Mohd Shahezwan Abd Wahab, Afonso Miguel Cavaco, Maria Magalhães, Erwin Martinez Faller, Jennifer M. Flores, Jacklyn Risia D. San Gabriel, Noordin Othman, Puree Anantachoti, Tatta Sriboonruang, Wanna Sriviriyanupap, Faris Alnezary, Yaser Alahmadi, Saad Bakur Fallatah, Haifa Abdulrahman Fadil, Carolina Oi Lam Ung
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: An estimated 80% of the world’s population use traditional and complementary medicine (T&CM) products as part of their healthcare, with many accessed through pharmacy. This cross-cultural study posed a set of professional practice res
Externí odkaz:
https://doaj.org/article/35ddaa2930a542c5867e986f3ed7ff33
Autor:
Truc T Tran, Nicolo L Cabrera, Anne J Gonzales-Luna, Travis J Carlson, Faris Alnezary, William R Miller, Aki Sakurai, An Q Dinh, Kirsten Rydell, Rafael Rios, Lorena Diaz, Blake M Hanson, Jose M Munita, Claudia Pedroza, Samuel A Shelburne, Samuel L Aitken, Kevin W Garey, Ryan Dillon, Laura Puzniak, Cesar A Arias
Publikováno v:
JAC-antimicrobial resistance. 5(1)
Background Ceftolozane/tazobactam is a β-lactam/β-lactamase inhibitor combination with activity against a variety of Gram-negative bacteria, including MDR Pseudomonas aeruginosa. This agent is approved for hospital-acquired and ventilator-associate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7655b909c98593dc990bcab21ffe5d8
https://pubmed.ncbi.nlm.nih.gov/36601551
https://pubmed.ncbi.nlm.nih.gov/36601551
Autor:
Nicolo Cabrera, Truc T Tran, Travis J Carlson, Faris Alnezary, William R Miller, An Q Dinh, Blake Hanson, Jose Munita, Samuel A Shelburne, Samuel L Aitken, Kevin W Garey, Laura A Puzniak, Cesar A Arias
Publikováno v:
Open Forum Infectious Diseases
Background Ceftolozane/tazobactam (C/T) is a novel cephalosporin/beta-lactamase inhibitor combination developed for use against multidrug-resistant (MDR) Gram-negative infections, particularly Pseudomonas aeruginosa (PA). C/T is approved for complica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aafa1ec006e10ea3994fce61402c0e2
http://europepmc.org/articles/PMC7777747
http://europepmc.org/articles/PMC7777747